ProfileGDS5678 / 1425552_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 37% 37% 40% 37% 35% 53% 36% 41% 39% 38% 39% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9458240
GSM967853U87-EV human glioblastoma xenograft - Control 22.8429937
GSM967854U87-EV human glioblastoma xenograft - Control 32.8501837
GSM967855U87-EV human glioblastoma xenograft - Control 42.8511940
GSM967856U87-EV human glioblastoma xenograft - Control 52.7964137
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8668535
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4014753
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7997136
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9346741
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8699339
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8685538
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8661839
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8789438
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8704938